Landos Biopharma Alpha and Beta Analysis
| LABPDelisted Stock | USD 4.02 0.15 3.60% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Landos Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Landos Biopharma over a specified time horizon. Remember, high Landos Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Landos Biopharma's market risk premium analysis include:
Beta (0.95) | Alpha 0.57 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Landos |
Landos Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Landos Biopharma market risk premium is the additional return an investor will receive from holding Landos Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Landos Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Landos Biopharma's performance over market.| α | 0.57 | β | -0.95 |
Landos Biopharma Fundamentals Vs Peers
Comparing Landos Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Landos Biopharma's direct or indirect competition across all of the common fundamentals between Landos Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Landos Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Landos Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Landos Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Landos Biopharma to competition |
| Fundamentals | Landos Biopharma | Peer Average |
| Return On Equity | -0.71 | -0.31 |
| Return On Asset | -0.39 | -0.14 |
| Current Valuation | 42.67 M | 16.62 B |
| Shares Outstanding | 3.13 M | 571.82 M |
| Shares Owned By Insiders | 9.88 % | 10.09 % |
| Shares Owned By Institutions | 52.04 % | 39.21 % |
| Number Of Shares Shorted | 1.43 K | 4.71 M |
Landos Biopharma Opportunities
Landos Biopharma Return and Market Media
The Stock received some media coverage during the period.About Landos Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Landos or other delisted stocks. Alpha measures the amount that position in Landos Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Landos Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Landos Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Landos Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Landos Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Landos Biopharma. Please utilize our Beneish M Score to check the likelihood of Landos Biopharma's management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Landos Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Landos Stock
If you are still planning to invest in Landos Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Landos Biopharma's history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |